---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001211"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-09-09T21:17:37+00:00"
generated_at: "2026-09-09T21:18:05.056534+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Anavex gets FDA meeting to discuss pediatric inclusion in Rett syndrome Phase 3 trial

## Summary
- FDA granted Anavex's request for a meeting to discuss adding pediatric patients to Phase 3 trial ANAVEX 2-73-RS-005 in Rett syndrome.
- Disclosure made September 9, 2026; trial targets adult patients with ANAVEX 2-73 (blarcamesine).
- Company prioritizing ANAVEX 2-73 development in early Alzheimer's, Rett, and Fragile X syndromes in the US.
- Meeting could expand trial scope to pediatric population, a potential label-expansion step.

## SEC filing metadata
- accession: 0001731122-26-001211
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-09-09T21:17:37+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/0001731122-26-001211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/e7928_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001211
- JSON: https://secwatch.observer/filing/0001731122-26-001211.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.